Project factsheets

Learn more about the projects supported by IHI as well as the Innovative Medicines Initiative (IMI).

IHI/IMI2/IMI1

Status

Call

Programmes

Disease areas

Products

Tools and resources to improve drug development

Clear all filters

Displaying 28 projects/programmes

ADAPT-SMART

Accelerated development of appropriate patient therapies: a sustainable, multi-stakeholder approach from research to treatment-outcomes

BD4BO

Big Data for Better Outcomes

Ongoing IMI2 Cardiovascular diseases Neurodegenerative diseases Cancer Alzheimer's disease BD4BO Patient involvement in R&D Big data and knowledge management Real-world data, evidence

BEAMER

Behavioral and adherence model for improving quality, health outcomes and cost-effectiveness of healthcare

Ongoing IMI2 Real-world data, evidence

BigData@Heart

Big data @ heart

Ongoing IMI2 Cardiovascular diseases BD4BO Big data and knowledge management Real-world data, evidence

COMBACTE-CDI

Combatting Bacterial Resistance in Europe - Clostridium Difficile Infections

Closed IMI2 Antimicrobial resistance Infectious diseases ND4BB Clinical trial design Clinical networks Real-world data, evidence

ConcePTION

Building an ecosystem for better monitoring and communicating of medication safety in pregnancy and breastfeeding: validated and regulatory endorsed workflows for fast, optimised evidence generation

Ongoing IMI2 Tools for predicting/monitoring safety Biobanks Big data and knowledge management Real-world data, evidence Tools for pediatrics

DO->IT

Big data for better outcomes, policy innovation and healthcare system transformation

Closed IMI2 BD4BO Big data and knowledge management Real-world data, evidence

DRIVE

Development of Robust and Innovative Vaccine Effectiveness

Closed IMI2 Infectious diseases Vaccines Tools for predicting/monitoring efficacy Real-world data, evidence

EHDEN

European Health Data and Evidence Network

Ongoing IMI2 BD4BO Big data and knowledge management Real-world data, evidence

GETREAL

Incorporating real-life clinical data into drug development

Closed IMI1 Clinical trial design Real-world data, evidence Regulatory and HTA processes

GetReal Initiative

The GetReal Initiative

Closed IMI2 Clinical trial design Real-world data, evidence Regulatory and HTA processes

H2O

H2O Health outcomes observatory

Ongoing IMI2 Diabetes & metabolic disorders Autoimmune diseases Cancer Patient involvement in R&D Real-world data, evidence

HARMONY

Healthcare alliance for resourceful medicines offensive against neoplasms in hematology

Ongoing IMI2 Cancer BD4BO Big data and knowledge management Real-world data, evidence

HARMONY PLUS

Healthcare alliance for resourceful medicines offensive against neoplasms in hematology – PLUS

Ongoing IMI2 Cancer BD4BO Big data and knowledge management Real-world data, evidence

IDEA-FAST

Identifying digital endpoints to assess fatigue, sleep and activities in daily living in neurodegenerative disorders and immune-mediated inflammatory diseases

Ongoing IMI2 Neurodegenerative diseases Autoimmune diseases Clinical trial design Digital health Real-world data, evidence

IDERHA

Integration of heterogeneous data and evidence towards regulatory and HTA acceptance

Ongoing IHI Cancer Digital health Big data and knowledge management Real-world data, evidence Imaging Artificial intelligence

MOBILISE-D

Connecting digital mobility assessment to clinical outcomes for regulatory and clinical endorsement

Ongoing IMI2 Cardiovascular diseases Neurodegenerative diseases Respiratory diseases Ageing-associated diseases Tools for predicting/monitoring efficacy Digital health Real-world data, evidence

ND4BB

New Drugs for Bad Bugs

Ongoing IMI1 Antimicrobial resistance Infectious diseases ND4BB Clinical trial design Conducting clinical trials Clinical networks Real-world data, evidence Drug discovery Economic model

NGN-PET

Modelling neuron-glia networks into a drug discovery platform for pain efficacious treatments

Closed IMI2 Pain Real-world data, evidence Drug discovery

OPTIMA

Optimal treatment for patients with solid tumours in Europe through artificial intelligence

Ongoing IMI2 Cancer Real-world data, evidence Artificial intelligence

PREFER

Patient Preferences in benefit risk assessments during the drug life cycle

Closed IMI2 Clinical trial design Patient involvement in R&D Real-world data, evidence Regulatory and HTA processes Methods for benefit/risk assessment

PREMIER

Prioritisation and risk evaluation of medicines in the environment

Ongoing IMI2 Real-world data, evidence Regulatory and HTA processes Environmental aspects

PROMINENT

Precision medicine platform in neurodegenerative disease

Ongoing IHI Neurodegenerative diseases Alzheimer's disease Digital health Big data and knowledge management Real-world data, evidence Artificial intelligence

ROADMAP

Real world outcomes across the AD spectrum for better care: multi-modal data access platform

Closed IMI2 Neurodegenerative diseases Alzheimer's disease BD4BO Big data and knowledge management Real-world data, evidence

SOPHIA

Stratification of obese phenotypes to optimize future obesity therapy

Ongoing IMI2 Diabetes & metabolic disorders Patient involvement in R&D Real-world data, evidence Disease taxonomy

Trials@Home

Center of excellence – remote decentralised clinical trials

Ongoing IMI2 Clinical trial design Digital health Real-world data, evidence Regulatory and HTA processes

VITAL

Vaccines and infectious diseases in the ageing population

Ongoing IMI2 Ageing-associated diseases Infectious diseases Vaccines Tools for predicting/monitoring efficacy Real-world data, evidence

WEB-RADR 2

Closed IMI2 Tools for predicting/monitoring safety Big data and knowledge management Real-world data, evidence Regulatory and HTA processes Methods for benefit/risk assessment